16,014 Shares in NewAmsterdam Pharma Company N.V. $NAMS Bought by Keybank National Association OH

Keybank National Association OH acquired a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 16,014 shares of the company’s stock, valued at approximately $455,000.

Several other hedge funds and other institutional investors have also made changes to their positions in NAMS. Arizona State Retirement System lifted its holdings in shares of NewAmsterdam Pharma by 3.8% in the 3rd quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock worth $377,000 after acquiring an additional 483 shares during the last quarter. Knights of Columbus Asset Advisors LLC raised its position in NewAmsterdam Pharma by 2.4% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 33,610 shares of the company’s stock worth $956,000 after purchasing an additional 777 shares during the period. New York State Common Retirement Fund bought a new stake in NewAmsterdam Pharma in the third quarter worth about $759,000. Jennison Associates LLC boosted its position in shares of NewAmsterdam Pharma by 42.5% during the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after buying an additional 1,252,451 shares during the period. Finally, Wolverine Asset Management LLC bought a new position in shares of NewAmsterdam Pharma during the third quarter valued at approximately $69,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Wall Street Analysts Forecast Growth

NAMS has been the topic of a number of recent analyst reports. Citigroup increased their target price on NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. HC Wainwright assumed coverage on NewAmsterdam Pharma in a research note on Monday, October 20th. They issued a “buy” rating and a $52.00 price objective on the stock. Leerink Partners reaffirmed an “outperform” rating and set a $55.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. The Goldman Sachs Group upped their target price on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a report on Tuesday, December 2nd. Finally, Needham & Company LLC raised their price target on NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.00.

NewAmsterdam Pharma Stock Down 2.8%

NewAmsterdam Pharma stock opened at $32.06 on Friday. NewAmsterdam Pharma Company N.V. has a twelve month low of $14.06 and a twelve month high of $42.00. The business has a fifty day moving average of $34.39 and a two-hundred day moving average of $31.61. The firm has a market cap of $3.64 billion, a P/E ratio of -15.64 and a beta of 0.06.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.03). The company had revenue of $0.35 million during the quarter, compared to the consensus estimate of $4.54 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%. Equities analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Insider Activity

In other news, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $33.25, for a total value of $199,500.00. Following the sale, the insider directly owned 73,481 shares in the company, valued at approximately $2,443,243.25. This trade represents a 7.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Louise Frederika Kooij sold 75,117 shares of the business’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $36.21, for a total transaction of $2,719,986.57. Following the transaction, the chief accounting officer owned 15,000 shares of the company’s stock, valued at approximately $543,150. This trade represents a 83.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 298,647 shares of company stock worth $10,236,050 in the last quarter. 20.84% of the stock is owned by insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.